Funding · Biotech
Shennon Biotechnologies raises $12M for T-cell engager pipeline
Its early pipeline includes programs for small-cell lung, ovarian and liver cancers.
Screening for functional T-cell therapies
Shennon’s TCELERATOR platform uses microfluidics to measure millions of single-cell interactions in one experiment, helping researchers identify T-cell engagers with activity against human tumor targets. The company combines that screening with therapeutic design and safety prediction to develop antibody- and T-cell-receptor-based programs; its candidates remain in early development.
Use of funds
Continue development of integrated technology platform
Advance oncology pipeline
Funding history
Funding · This round$12M